Circulating endothelial cells and tumor blood volume as predictors in lung cancer

Abstract

The current criteria for evaluating antiangiogenic efficacy is insufficient as tumor shrinkage occurs after blood perfusion decreases. Tumor blood volume (BV) in computed tomography perfusion imaging and circulating endothelial cells (CEC) might predict the status of angiogenesis. The present study aimed to validate their representation as feasible predictors in non-small-cell lung carcinoma (NSCLC). A total of 74 patients was categorized randomly into two arms undergoing regimens of vinorelbine and cisplatin (Navelbine and platinum [NP]) with rh-endostatin or single NP. The response rate, perfusion imaging indexes and activated CEC (aCEC) during treatment were recorded. Progression-free survival (PFS) was determined through follow up. Correlations among the above indicators, response and PFS were analyzed: aCEC increased significantly in cases of progressive disease after single NP chemotherapy (P = 0.024). Tumor BV decreased significantly in cases with a clinical benefit in the combined arm (P = 0.026), whereas inverse correlations existed between ΔaCEC (posttherapeutic value minus the pre-therapeutic value) and PFS (P = 0.005) and between ΔBV and PFS (P = 0.044); a positive correlation existed between ΔaCEC and ΔBV. Therefore, both aCEC and tumor BV can serve as predictors, and detection of both indicators can help evaluate the chemo-antiangiogenic efficacy in NSCLC more accurately. (Cancer Sci 2013; 104: 445-452)

The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?

“…The authors reported a positive correlation of baseline counts with good prognosis. After all, in congruence with other works, a decrease in both circulating EnC and EPC correlated with a longer PFS or OS in the majority of studies, before and after effective anti-angiogenic therapy and/or chemotherapy [85,86] Polyploidy is a common cellular cancer marker and has been included into investigations on circulating EnC [34,87,88]. Latest work on the topic may come from Zhang et al [88], employing Cytelligen's SE-iFISH to identify PD-L1 positive, aneuploid circulating EnC (multiploidy in chromosme 8) assumed to be tumor-associated and investigating their usefulness as companion diagnostic as to predict resistance to checkpoint blockade immunotherapy in advanced NSCLC patient [88].…”

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

“…The later study by Li et al [78] included a total of 85 patients with locally advanced or metastatic NSCLC who underwent NP chemotherapy, alone or combined with rh-endostatin. In the chemotherapy group, the aCECs values were negatively correlated with the tumor progression time (p = 0.036) in the combined treatment group.…”

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture

“…Another clinical study on NSCLC patients treated with anti-angiogenic chemotherapy also showed that tumour vascular volume was reduced significantly in responders versus non-responders [40] . In addition, decreased tumour blood volume during antiangiogenic therapy was associated with a clinic benefit in lung cancer patients [41] .…”